Anti-GP179/ GPR179/ CSNB1E monoclonal antibody

Anti-GP179/ GPR179/ CSNB1E antibody for FACS & in-vivo assay

Target products collectionGo to GPR179/GPR179 products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-MP0525-Ab-1/ GM-Tg-hg-MP0525-Ab-2Anti-Human GPR179 monoclonal antibodyHuman
GM-Tg-rg-MP0525-Ab-1/ GM-Tg-rg-MP0525-Ab-2Anti-Rat GPR179 monoclonal antibodyRat
GM-Tg-mg-MP0525-Ab-1/ GM-Tg-mg-MP0525-Ab-2Anti-Mouse GPR179 monoclonal antibodyMouse
GM-Tg-cynog-MP0525-Ab-1/ GM-Tg-cynog-MP0525-Ab-2Anti-Cynomolgus/ Rhesus macaque GPR179 monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-MP0525-Ab-1/ GM-Tg-felg-MP0525-Ab-2Anti-Feline GPR179 monoclonal antibodyFeline
GM-Tg-cang-MP0525-Ab-1/ GM-Tg-cang-MP0525-Ab-2Anti-Canine GPR179 monoclonal antibodyCanine
GM-Tg-bovg-MP0525-Ab-1/ GM-Tg-bovg-MP0525-Ab-2Anti-Bovine GPR179 monoclonal antibodyBovine
GM-Tg-equg-MP0525-Ab-1/ GM-Tg-equg-MP0525-Ab-2Anti-Equine GPR179 monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-MP0525-Ab-1/ GM-Tg-hg-MP0525-Ab-2; GM-Tg-rg-MP0525-Ab-1/ GM-Tg-rg-MP0525-Ab-2;
GM-Tg-mg-MP0525-Ab-1/ GM-Tg-mg-MP0525-Ab-2; GM-Tg-cynog-MP0525-Ab-1/ GM-Tg-cynog-MP0525-Ab-2;
GM-Tg-felg-MP0525-Ab-1/ GM-Tg-felg-MP0525-Ab-2; GM-Tg-cang-MP0525-Ab-1/ GM-Tg-cang-MP0525-Ab-2;
GM-Tg-bovg-MP0525-Ab-1/ GM-Tg-bovg-MP0525-Ab-2; GM-Tg-equg-MP0525-Ab-1/ GM-Tg-equg-MP0525-Ab-2
Products NameAnti-GPR179 monoclonal antibody
Formatmab
Target NameGPR179
Protein Sub-locationTransmembrane Protein
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by using flow cytometry with antigen overexpressed cell line. The biofunction of antibodies are validated in cell-based assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-GPR179 benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, FACS,ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenProducts DevelopingMulti-species GP179/ GPR179/ CSNB1E VLP (virus-like particle) (Products Developing)


    Target information

    Target IDGM-MP0525
    Target NameGPR179
    Gene ID440435,217143,287657,693410,491040,101098590,787335,100069089
    Gene Symbol and Synonyms5330439C02Rik,CSNB1E,GPR158L,GPR158L1,GPR179,RGD1560033
    Uniprot AccessionQ6PRD1
    Uniprot Entry NameGP179_HUMAN
    Protein Sub-locationTransmembrane Protein
    Category
    DiseaseN/A
    Gene EnsemblENSG00000277399
    Target ClassificationN/A

    The target: GPR179, gene name: GPR179, also named as CSNB1E, GPR158L, GPR158L1. This gene encodes a member of the glutamate receptor subfamily of G protein-coupled receptors. The encoded protein has an EGF-like calcium binding domain and a seven transmembrane domain in the N-terminal region of the protein. Mutations in this gene are associated with congenital stationary night blindness type 1E. [provided by RefSeq, Apr 2012].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.